Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Kewen Jin


Kewen Jin, general manager of Charles River Laboratories China, a contract research organization for preclinical services, discusses the opportunities and challenges for Shanghai.

What trends are emerging in Shanghai's life-science community?

We see people moving between academia, large companies and start-ups. Many do research during the day, and write business plans and talk to venture capitalists at night. Leading academics might join pharmaceutical centres, or leaders of pharmaceutical research companies might head a start-up.

What personnel does Shanghai's life-sciences industry most need?

Pathologists, toxicologists, medicinal chemists and clinicians with experience in global trials. They are difficult to get because, whether foreigners or expatriate Chinese, most are overseas; those with enough experience are in short supply. They get compensation packages: housing allowances, coverage for their children's schools, or other benefits.

Are there jobs in junior positions?

Discovery operations are expanding, so there is a need for senior and junior researchers. But most of the junior positions are filled with local candidates. It is an availability and cost issue.

How do tightening business conditions for drug makers in the West affect China?

There is a push and pull. The pull is Chinese opportunities. The push is downsizing in the West. Lots of Chinese researchers still go to the West for their postdocs, but they are less likely to stay. I see many résumés that are extremely qualified and not Chinese. Some applicants are mid-career and have been laid off. But there are some at the start of their careers who came to see what it's like here and decided to stay.

Why are Charles River's expansion plans in China on hold?

There has been little demand for preclinical services, because many companies are just setting up. It takes a few years to get to preclinical development. It will be some time before the industries feel comfortable using Chinese data for global regulatory filings, but we are getting there, with research that is comparable in quality to Western studies.

Do you have advice for anyone seeking a research post in Shanghai?

You may not get an ideal offer at first. Don't be picky. Once you're here, you can network.


Additional information

Interview and statistics by David Cyranoski.

Related links

Related links

Related links in Nature Research

Charles River downsizes

China moves to help high-tech firms

China's research rise

Enter the dragon

Related external links

Charles River Laboratories China

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cyranoski, D. Kewen Jin. Nature 466, 518 (2010).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing